Cargando…
Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy
The purpose of this study was to evaluate the efficacy of low-dose chemotherapy in infants with localised and unresectable neuroblastoma (NB). All consecutive infants with localised NB and no N-myc amplification were eligible in the SFOP-NBL 94 study. Primary tumour was deemed as unresectable accord...
Autores principales: | Rubie, H, Coze, C, Plantaz, D, Munzer, C, Defachelles, A S, Bergeron, C, Thomas, C, Chastagner, P, Valteau-Couanet, D, Michon, J, Mosseri, V, Hartmann, O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394428/ https://www.ncbi.nlm.nih.gov/pubmed/14583756 http://dx.doi.org/10.1038/sj.bjc.6601259 |
Ejemplares similares
-
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007) -
Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
por: Rubie, H., et al.
Publicado: (1998) -
Treatment of stage 4s neuroblastoma – report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)
por: Schleiermacher, G, et al.
Publicado: (2003) -
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology
por: Minard, V, et al.
Publicado: (2000) -
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
por: De Bernardi, B, et al.
Publicado: (2008)